After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.
Advertisement
Bio Business
Most Recent
Fueled by donations, sweat, and occasional dumpster diving, community laboratories for DIY biologists are cropping up around the country.
Affordable diagnostic tests tackle the world’s most pressing health problems.
After two headline successes, companies rush to develop “smart bomb” cancer drugs.
Biological resource centers are bigger and better than ever before, storing and distributing shared reagents, plasmids, and more.
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.
A Swiss-based firm may have a back-door way to thwart a bioterrorist attack—by fighting the flu.
From iPhone apps to cloud computing, everyday digital technologies are helping advance drug discovery, conduct clinical trials, and improve medical care.
Subjects
- biobusiness
- biotech
- business
- cancer
- cell & molecular biology
- clinical trials
- disease/medicine
- drug development
- FDA
- regulation
Sub Categories
- Bio Business
- Capsule Reviews
- Careers
- Contributors
- Critic At Large
- Editorial
- Features
- Foundations
- Lab Tools
- Modus Operandi
- Notebook
- Profile
- Reading Frames
- Scientist to Watch
- Speaking of Science
- The Literature
- Thought Experiment
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
